Advanced

HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis

Wassmuth, R; Depner, F; Danielsson, A; Hultcrantz, R; Loof, L; Olson, R; Prytz, Hanne LU ; Sandberg-Gertzen, H; Wallerstedt, S and Lindgren, S (2002) In Tissue Antigens 59(5). p.381-387
Abstract
Genetic susceptibility to PBC can, at least in part, be ascribed to the major histocompatibility complex. The relevance of immunogenetic markers for the clinical presentation and course, however, is unclear. Thus, the aim of this study was to investigate the contribution of HLA class II genes to susceptibility, clinical presentation and course of disease in PBC patients. HLA genotyping for HLA-DRB1, -DQB1 and -DPB1 was carried out in a total of 99 Swedish PBC patients and 158 controls. Clinical parameters including epidemiologic variables, signs and symptoms of PBC-related liver disease and histologic data were collected and analyzed in 92 patients at study entry and at follow-up five years later. Significant clinical heterogeneity was... (More)
Genetic susceptibility to PBC can, at least in part, be ascribed to the major histocompatibility complex. The relevance of immunogenetic markers for the clinical presentation and course, however, is unclear. Thus, the aim of this study was to investigate the contribution of HLA class II genes to susceptibility, clinical presentation and course of disease in PBC patients. HLA genotyping for HLA-DRB1, -DQB1 and -DPB1 was carried out in a total of 99 Swedish PBC patients and 158 controls. Clinical parameters including epidemiologic variables, signs and symptoms of PBC-related liver disease and histologic data were collected and analyzed in 92 patients at study entry and at follow-up five years later. Significant clinical heterogeneity was seen among PBC patients upon study entry. Although a significant disease association was seen for HLA DRB1*08 and DQB1*0402, immunogenetic markers identified neither a particular subset of patients nor an association with the clinical course of the disease. HLA-DRB1*08 and DQB1*0402 provide the strongest immunogenetic influence in PBC. However, this association is not restricted to any particular, clinically defined subgroup of patients and it is not predictive for the course of the disease. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
primary biliary cirrhosis, liver disease, histocompatibility antigens, HLA class II antigens
in
Tissue Antigens
volume
59
issue
5
pages
381 - 387
publisher
Wiley-Blackwell
external identifiers
  • wos:000177088700004
  • pmid:12144621
  • scopus:0036024561
ISSN
0001-2815
DOI
10.1034/j.1399-0039.2002.590504.x
language
English
LU publication?
yes
id
edc29c62-f344-49f8-9b95-62e464a8966f (old id 332491)
date added to LUP
2007-11-09 15:31:59
date last changed
2017-11-15 14:17:22
@article{edc29c62-f344-49f8-9b95-62e464a8966f,
  abstract     = {Genetic susceptibility to PBC can, at least in part, be ascribed to the major histocompatibility complex. The relevance of immunogenetic markers for the clinical presentation and course, however, is unclear. Thus, the aim of this study was to investigate the contribution of HLA class II genes to susceptibility, clinical presentation and course of disease in PBC patients. HLA genotyping for HLA-DRB1, -DQB1 and -DPB1 was carried out in a total of 99 Swedish PBC patients and 158 controls. Clinical parameters including epidemiologic variables, signs and symptoms of PBC-related liver disease and histologic data were collected and analyzed in 92 patients at study entry and at follow-up five years later. Significant clinical heterogeneity was seen among PBC patients upon study entry. Although a significant disease association was seen for HLA DRB1*08 and DQB1*0402, immunogenetic markers identified neither a particular subset of patients nor an association with the clinical course of the disease. HLA-DRB1*08 and DQB1*0402 provide the strongest immunogenetic influence in PBC. However, this association is not restricted to any particular, clinically defined subgroup of patients and it is not predictive for the course of the disease.},
  author       = {Wassmuth, R and Depner, F and Danielsson, A and Hultcrantz, R and Loof, L and Olson, R and Prytz, Hanne and Sandberg-Gertzen, H and Wallerstedt, S and Lindgren, S},
  issn         = {0001-2815},
  keyword      = {primary biliary cirrhosis,liver disease,histocompatibility antigens,HLA class II antigens},
  language     = {eng},
  number       = {5},
  pages        = {381--387},
  publisher    = {Wiley-Blackwell},
  series       = {Tissue Antigens},
  title        = {HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis},
  url          = {http://dx.doi.org/10.1034/j.1399-0039.2002.590504.x},
  volume       = {59},
  year         = {2002},
}